Contraindications
Hypersensitivity. Premature infants or neonates (≤2 months). Pregnancy (near or at term).
|
Special Precautions
Patient with hypersensitivity to sulfonamide derived medicines, G6PD deficiency. Not recommended for use in very exudative leg or pressure ulcers. Hepatic and renal impairment. Lactation. Monitoring Parameters Perform urinalysis, renal function tests, CBC (patient with extensive burns and on long-term treatment). Monitor serum electrolytes; serum sulfa concentrations (as necessary).
|
Adverse Reactions
Significant: Fungal or bacterial superinfection including C.difficile-associated diarrhoea (CDAD) and pseudomembranous colitis, leucopenia (prolonged use); delayed eschar separation. Rarely, fungal proliferation.
General disorders and administration site conditions: Application site burning.
Immune system disorders: Hypersensitivity reactions.
Skin and subcutaneous tissue disorders: Pruritus, rash, eczema, contact dermatitis, erythema multiforme, skin discolouration, photosensitivity. Rarely, Argyria (prolonged use/large area of application).
Potentially Fatal: Stevens-Johnson syndrome. |
B
Silver sulfadiazine is not recommended during near term pregnancy due to the potential risk of neonatal hyperbilirubinaemia and kernicterus.
|
Drug Interactions
May inactivate enzymatic debriding agents. May alter the effects of oral hypoglycaemic agents and phenytoin (application in large areas).
|
CIMS Class
|
ATC Classification
D06BA01 - silver sulfadiazine ; Belongs to the class of topical sulfonamides used in the treatment of dermatological diseases.
|